Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We have investigated the role of globus pallidus (GP) serotonergic terminals in the development of levodopa-induced dyskinesias (LIDs) in Parkinson's disease (PD). We studied 12 PD patients without LIDs, 12 PD patients with LIDs, and 12 healthy control subjects. We used (11)C-DASB positron emission tomography (PET), a marker of serotonin transporter availability, and (11)C-raclopride PET to measure changes in synaptic dopamine levels following levodopa administration. PD patients without LIDs showed a significant reduction of GP serotonin transporter binding compared with healthy controls although this was within the normal range in PD patients with LIDs. Levels of GP serotonin transporter binding correlated positively with severity of dyskinesias. (11)C-raclopride PET detected a significant rise in GP synaptic dopamine levels of patients with LIDs after a levodopa challenge but not in patients with a stable response. Our findings indicate that LIDs in PD are associated with higher GP serotonergic function. This increased serotonin function may result in further dysregulation of thalamocortical signals and so promote the expression of dyskinesias.

Original publication

DOI

10.1016/j.neurobiolaging.2014.12.037

Type

Journal article

Journal

Neurobiol Aging

Publication Date

04/2015

Volume

36

Pages

1736 - 1742

Keywords

Dyskinesia, Globus pallidus, Parkinson's disease, Positron emission tomography, Serotonin, Aged, Dopamine, Dyskinesias, Female, Globus Pallidus, Humans, Levodopa, Male, Middle Aged, Parkinson Disease, Positron-Emission Tomography, Protein Binding, Serotonergic Neurons, Serotonin, Serotonin Plasma Membrane Transport Proteins, Severity of Illness Index, Synapses